2.1. Study Design and Population
RA, eating disorders
The present study is a post-hoc analysis of a randomized controlled clinical trial (NutriFast) that we reported earlier [Between March 2019 and November 2020, we enrolled and randomized participants with RA on stable medication who were healthy enough to participate in an outpatient fasting program. Key exclusion criteria included previous eating disorders, underweight status, a strict plant-based diet and/or fasting within the last six months, as well as changes in therapy with DMARDs in the last 8 weeks before enrolment [